<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Question</title></head><body><div><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by the Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO) (BTO0028)</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Question. Are UK policies governing who can donate blood and blood products, tissues and organs sufficiently evidence-based?</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:normal">1.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Yes.  SaBTO has worked with the UK blood services, the UK health departments and the </span><span style="font-family:'Times New Roman'; font-size:11pt">r</span><span style="font-family:'Times New Roman'; font-size:11pt">egulators to ensure that UK policies on who can donate blood and blood products, tissues and organs are evidence-based.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:normal">1.2</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">For example we provided advice on the donor deferral of men who have had sex with men in relation to blood donation in 2011 and in relation to tissue and cell donation in 2013.  Our advice, which is based on the UK evidence base, has been accepted and implemented in England, Scotland and Wales.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Question. Is NHS Blood and Transplant overly restrictive about who can donate, or should greater precautions be taken to further reduce risk?</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">2.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">No.  The UK blood services are required to meet the requirements of the Blood Safety and Quality Regulations 2005, which derive from requirements set by a number of EU Directives.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">2.2</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO supports the UK blood services</span><span style="font-family:'Times New Roman'; font-size:11pt">’ approach to donor selection</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">that</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> within the regulatory structure</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> ensure</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> that evidence based donor </span><span style="font-family:'Times New Roman'; font-size:11pt">deferral and exclusion </span><span style="font-family:'Times New Roman'; font-size:11pt">policies are appropriate for the UK donor population.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Question. Is the Government and its scientific advisory structure sufficiently responsive to the threat posed by emerging diseases being transmitted through blood and blood products, tissues and organs?</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">3.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO currently provides robust independent scientific evidence based advice to Government on matters within the Committee</span><span style="font-family:'Times New Roman'; font-size:11pt">’</span><span style="font-family:'Times New Roman'; font-size:11pt">s remit (attached at A</span><span style="font-family:'Times New Roman'; font-size:11pt">ppendi</span><span style="font-family:'Times New Roman'; font-size:11pt">x A).  Details of current members and their short biographies are at A</span><span style="font-family:'Times New Roman'; font-size:11pt">ppendi</span><span style="font-family:'Times New Roman'; font-size:11pt">x B.  Advice from SaBTO is provided to all four UK health departments.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">3.2</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO was established in 2008, replacing a previous committee with a narrower remit</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> the </span><span style="font-family:'Times New Roman'; font-size:11pt">Advisory Committee on the Microbiological Safety of Blood, Tissues &amp; Organs for Transplantation (MSBTO).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">3.3</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO works closely with other committees where interests are common, including the National Expert Panel on New and Emerging Infections (NEPNEI) and the Advisory Committee on Dangerous Pathogens (ACDP).</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">In addition, SaBTO does not only rely on the (considerable) experience of its </span><span style="font-family:'Times New Roman'; font-size:11pt">constituent</span><span style="font-family:'Times New Roman'; font-size:11pt"> members. </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Rather, </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO’s key working method </span><span style="font-family:'Times New Roman'; font-size:11pt">is to establish</span><span style="font-family:'Times New Roman'; font-size:11pt"> short term working groups </span><span style="font-family:'Times New Roman'; font-size:11pt">that comprise both </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO members and additional experts</span><span style="font-family:'Times New Roman'; font-size:11pt"> outside SaBTO. </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">This has been particularly effective in enabling SaBTO to work responsively, effectively, and with a wide evidence base. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">With regard to new and emerging threats SaBTO has </span><span style="font-family:'Times New Roman'; font-size:11pt">recently advised</span><span style="font-family:'Times New Roman'; font-size:11pt"> on the UK use of blood tests for West Nile Virus (WNV), an increasing potential threat as this disease becomes increasingly prevalent in Mediterranean areas frequented by UK tourists.  In 2013 SaBTO also produced a statement of advice on WNV and Solid Organ Transplantation.</span><span style="font-family:'Times New Roman'; font-size:11pt">  Earlier SaBTO had provided </span><span style="font-family:'Times New Roman'; font-size:11pt">advice </span><span style="font-family:'Times New Roman'; font-size:11pt">d</span><span style="font-family:'Times New Roman'; font-size:11pt">uring the influenza A (H1N1)pdm09 </span><span style="font-family:'Times New Roman'; font-size:11pt">pandemic on the implications for organ donation. Subsequently in August 2011</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> SaBTO published advice on organ donation and seasonal </span><span style="font-family:'Times New Roman'; font-size:11pt">influenza.</span><span style="font-family:'Times New Roman'; font-size:11pt">  SaBTO has set up a short life working group which will meet shortly to consider issues related to hepatitis E.  SaBTO also keeps a watching brief on the implications of emerging </span><span style="font-family:'Times New Roman'; font-size:11pt">infections</span><span style="font-family:'Times New Roman'; font-size:11pt"> such Middle East Respiratory Syndrome (MERS). </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">4.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO papers and minutes of meetings are publically available, redacted where appropriate for reasons </span><span style="font-family:'Times New Roman'; font-size:11pt">such as</span><span style="font-family:'Times New Roman'; font-size:11pt"> commercial confidentiality, at:</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><a href="https://www.gov.uk/government/policy-advisory-groups/advisory-committee-on-the-safety-of-blood-tissues-and-organs"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/policy-advisory-groups/advisory-committee-on-the-safety-of-blood-tissues-and-organs</span></a></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Question. Has the threat of ongoing transmission of variant Creutzfeldt-Jakob disease (vCJD) through the blood and blood product supply been adequately mitigated?</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">5.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO has, from its foundation, taken a continuing interest in prion disease, and has reviewed existing and potential new risk reduction measures.  SaBTO’s summary of such measures is available at:</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><a href="https://www.gov.uk/government/publications/current-measures-to-reduce-the-risk-of-vcjd-transmission-by-blood"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/publications/current-measures-to-reduce-the-risk-of-vcjd-transmission-by-blood</span></a></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">5.2</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO has considered potential new prion disease risk reduction measures as they come forward, and has provided advice when appropriate evidence is available.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">5.3</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO, and in particular SaBTO’s </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD Sub G</span><span style="font-family:'Times New Roman'; font-size:11pt">roup, has considered and used the latest version of the </span><span style="font-family:'Times New Roman'; font-size:11pt">analytical </span><span style="font-family:'Times New Roman'; font-size:11pt">paper “</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">vCJD and transfusion of blood components: An updated risk assessment</span><span style="font-family:'Times New Roman'; font-size:11pt">” in its work.  SaBTO is reassured that the latest evidence is used in development of this paper and that the Department remains committed to further revisions as and when significant new evidence becomes available.  SaBTO has noted that the latest edition of the paper, publically available at: </span><a href="https://www.gov.uk/government/publications/vcjd-and-transfusion-of-blood-components-updated-risk-assessment"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/publications/vcjd-and-transfusion-of-blood-components-updated-risk-assessment</span></a><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">takes into account the most recent evidence on the prevalence of abnormal prion protein in archived UK appendix tissue.  SaBTO recently used the risk assessment when considering</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> at the September 2013 meeting</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> the sourcing of platelets by apheresis; relevant papers and minutes are publically available at:</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><a href="https://www.gov.uk/government/policy-advisory-groups/advisory-committee-on-the-safety-of-blood-tissues-and-organs"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/policy-advisory-groups/advisory-committee-on-the-safety-of-blood-tissues-and-organs</span></a></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">5.4</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO recognises that the assumptions used in the risk assessment paper are p</span><span style="font-family:'Times New Roman'; font-size:11pt">recautionary in approach, but currently considers this appropriate whilst many scientific uncertainties remain with regard to prions in general and vCJD in particular.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">5.5</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO recognises that further risk reduction measures may be proposed in the </span><span style="font-family:'Times New Roman'; font-size:11pt">future including the development and potential use of blood tests for detecting vCJD infection,</span><span style="font-family:'Times New Roman'; font-size:11pt"> which may help health services take more targeted action.  However in all cases SaBTO would wish to consider the potential implications for introduction of such measures not only for the services themselves but for each donor and recipient.  SaBTO acknowledges the important contribution to such potential future considerations provided by the Department of Health’s 2009 paper </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Mapping out the consequences of screening blood donations for PrP</span><span style="font-family:'Times New Roman'; font-size:7.33pt; font-style:italic; vertical-align:super">Sc</span><span style="font-family:'Times New Roman'; font-size:11pt">.  If ever a test were to be considered for introduction</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> SaBTO would consider </span><span style="font-family:'Times New Roman'; font-size:11pt">amongst other issues </span><span style="font-family:'Times New Roman'; font-size:11pt">the levels of </span><span style="font-family:'Times New Roman'; font-size:11pt">sensitivity and specificity of the test (the highest possible would be </span><span style="font-family:'Times New Roman'; font-size:11pt">necessary </span><span style="font-family:'Times New Roman'; font-size:11pt">with the requirements set by the IVD Directive as a minimum), the availability of </span><span style="font-family:'Times New Roman'; font-size:11pt">a </span><span style="font-family:'Times New Roman'; font-size:11pt">confirmatory assay (no test on donors could be considered without one), and the views of donors and recipients (particularly from heavily transfused individuals </span><span style="font-family:'Times New Roman'; font-size:11pt">including </span><span style="font-family:'Times New Roman'; font-size:11pt">sickle, thalassaemia and myelodysplasia patients).</span></p><p style="margin:0pt"><br style="page-break-before:always; clear:both" /></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Question. What are the strengths and weaknesses of NHS Blood and Transplant’s strategy, “Taking Organ Transplantation to 2020”?</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">6.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO welcomes the success to date of the strategy, and notes that the NHSBT remains committed to patient </span><span style="font-family:'Times New Roman'; font-size:11pt">welfare</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">6.2</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO has a current workstream on Donor Organ Risk Assessment (DORA) aimed at providing evidence based advice on the use of organs available for transplant.  The DORA </span><span style="font-family:'Times New Roman'; font-size:11pt">working group is reviewing</span><span style="font-family:'Times New Roman'; font-size:11pt"> the evidence base for decision making in organ acceptance and transplantation, looking particularly at specific diagnoses, donor behaviours and characterisations. SaBTO will produce a series of guidance documents and/or position papers, reflecting the best available evidence, to support decision making and identify where any changes in practice would be beneficial.  The aim of the guidance will be to inform clinicians and patients and support shared decision making</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> and to maximise the successful transplantation of patients and the utilisation of suitable organs.  The first piece of guidance in this programme should be available in 2014 and will cover </span><span style="font-family:'Times New Roman'; font-size:11pt">the use of organs from deceased donors with cancer or a history of cancer.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Question. What further changes could be made to safely increase the supply of blood and blood products, tissues and organs?</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">7.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">This is </span><span style="font-family:'Times New Roman'; font-size:11pt">mainly </span><span style="font-family:'Times New Roman'; font-size:11pt">a question for </span><span style="font-family:'Times New Roman'; font-size:11pt">NHSBT (for organ donation across </span><span style="font-family:'Times New Roman'; font-size:11pt">the UK</span><span style="font-family:'Times New Roman'; font-size:11pt">), </span><span style="font-family:'Times New Roman'; font-size:11pt">the UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> blood services</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and others </span><span style="font-family:'Times New Roman'; font-size:11pt">(for blood and tissue donation)</span><span style="font-family:'Times New Roman'; font-size:11pt">.  </span><span style="font-family:'Times New Roman'; font-size:11pt">That said, SaBTO's remit includes a consideration of the sufficiency of supply of blood, tissues and organs and this factor is taken into account in all major discussions both at the main SaBTO meetings and within working group sessions</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">7.2</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">One aspect of this is how better to use the Donation after Cardiac Death (DCD) donor.  The use of extracorporeal normothermic perfusion of DCD donations may recover more DCD organs and improve accessibility to organs.  </span><span style="font-family:'Times New Roman'; font-size:11pt">A second development would be to </span><span style="font-family:'Times New Roman'; font-size:11pt">review </span><span style="font-family:'Times New Roman'; font-size:11pt">the provision of organ donor screening by NHSBT which </span><span style="font-family:'Times New Roman'; font-size:11pt">may provide opportunities for improved service, </span><span style="font-family:'Times New Roman'; font-size:11pt">particular</span><span style="font-family:'Times New Roman'; font-size:11pt">ly with regard to</span><span style="font-family:'Times New Roman'; font-size:11pt"> more unusual testing for </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">T cruzi</span><span style="font-family:'Times New Roman'; font-size:11pt"> and malaria. </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">It </span><span style="font-family:'Times New Roman'; font-size:11pt">may </span><span style="font-family:'Times New Roman'; font-size:11pt">also encourage better and more definitive</span><span style="font-family:'Times New Roman'; font-size:11pt"> “</span><span style="font-family:'Times New Roman'; font-size:11pt">confirmatory” testing.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Question. What lessons could be learnt from the screening and donation practices of other countries?</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">8.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Information from other countries is, often, obtained prior to decision making. </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">For example, when providing</span><span style="font-family:'Times New Roman'; font-size:11pt"> advice on proposals that affect screening and donation practices SaBTO, where appropriate, considers practices in </span><span style="font-family:'Times New Roman'; font-size:11pt">and evidence from </span><span style="font-family:'Times New Roman'; font-size:11pt">other countries.  </span><span style="font-family:'Times New Roman'; font-size:11pt">Instances include when it </span><span style="font-family:'Times New Roman'; font-size:11pt">advised on MSM donor deferrals, provision of </span><span style="font-family:'Times New Roman'; font-size:11pt">cytomegalovirus seronegative</span><span style="font-family:'Times New Roman'; font-size:11pt"> bl</span><span style="font-family:'Times New Roman'; font-size:11pt">ood and West Nile Virus testing</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">  The upcoming discussions on hepatitis E screening will take account of the wider EU practices</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">January 2014</span><br style="page-break-before:always; clear:both" /></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">A</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ppendix</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> A</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Terms of Reference for the Advisory Committee on the Safety of Blood,</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Tissues and Organs (SaBTO)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The Committee will advise Ministers of the UK Government and the Devolved Administrations as well as UK Health Departments on the most appropriate ways to ensure the safety of blood, cells, tissues and organs for transfusion / transplantation. Its remit includes providing advice on the microbiological safety of gametes and stem cells, in liaison with the relevant regulatory authorities. The Committee will provide independent advice on risk management for Ministers and UK Health Departments to consider.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">In formulating its advice, the Committee will:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">take into account sufficiency of supply, and the need to maintain adequate supplies of blood, cells (including gametes and stem cells), tissues and organs of appropriate quality;</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">consider the efficacy of transfusion / transplantation and consider the cost-effectiveness of interventions, including the introduction of new safety measures and/or the reduction, phasing out or withdrawal of current measures;</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">interpret and where appropriate, commission risk assessments from a wide range of sources, including DH and Health Protection Agency Analysts, UK Blood Services, other advisory committees such as the Advisory Committee on Dangerous Pathogens, and independent researchers;</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">take full account of scientific uncertainty and assumptions used in reaching conclusions, and clearly convey the nature and extent of such uncertainties with its advice;</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">identify where research to reduce uncertainty is most urgently required, and where possible identify specific research needs;</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">monitor and influence the EU Directives on blood, cells, tissues and organs to ensure that the guidance of the committee is consistent with the directives in conjunction with the relevant competent authorities;</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">consider the potential impact of its advice on both donors and recipients.</span></li></ul><p style="margin:0pt; text-align:justify"><br style="page-break-before:always; clear:both" /></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">A</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ppendi</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">x B</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><h2 style="margin:0pt; page-break-after:avoid; page-break-inside:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">SaBTO Membership – January 2014</span></h2><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Professor John Forsythe (Chair – </span><span style="font-family:'Times New Roman'; font-size:11pt">Abdominal </span><span style="font-family:'Times New Roman'; font-size:11pt">transplant surgeon)</span></li></ul><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Professor John Cairns (health economist)</span></li><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Paul De Sousa (regenerative medicine specialist)</span></li><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Dr George Galea (Co-opted - blood/transplant service manager)</span></li><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Kate Gould (microbiologist/bacteriologist/virologist)</span></li><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Mrs Gill Hollis (patient representative)</span></li><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Mrs Catherine Howell (nurse)</span></li><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Richard Knight (prion disease specialist)</span></li><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Harpreet Kohli (epidemiologist/public health specialist)</span></li><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Eithne MacMahon (microbiologist/bacteriologist/virologist)</span></li><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Alison Murdoch (IVF/fertility/stem cell specialist)</span></li><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Mallika Sekhar (haematologist)</span></li><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Tom Solomon (microbiologist/bacteriologist/virologist)</span></li><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Glyn Stacey (Co-opted - stem cell banking specialist) </span></li><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Professor the Hon. Richard Tedder (microbiologist/bacteriologist/virologist)</span></li><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Marc Turner (Co-opted haematologist)</span></li><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Anthony Warrens (immunologist)</span></li><li style="font-family:Symbol; font-size:10pt; margin:0pt 0pt 0pt 27.6pt; padding-left:8.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Lorna Williamson (blood service medical director)</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:right"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p></div></body></html>